Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Daniel Bowles

Concepts (339)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Agents
29
2024
1875
3.670
 Why?
Head and Neck Neoplasms
16
2023
427
3.340
 Why?
Salivary Gland Neoplasms
8
2023
31
3.110
 Why?
Carcinoma, Squamous Cell
14
2019
577
2.440
 Why?
Protein Kinase Inhibitors
12
2024
784
2.230
 Why?
Pyridines
11
2024
419
2.220
 Why?
Thyroid Neoplasms
8
2024
271
1.950
 Why?
Neoplasm Recurrence, Local
7
2023
850
1.900
 Why?
Carcinoma, Non-Small-Cell Lung
8
2023
959
1.860
 Why?
Molecular Targeted Therapy
7
2021
347
1.840
 Why?
Antineoplastic Combined Chemotherapy Protocols
13
2019
1356
1.670
 Why?
Protein-Tyrosine Kinases
4
2021
393
1.560
 Why?
Lung Neoplasms
10
2023
2159
1.530
 Why?
Neoplasms
17
2022
2086
1.520
 Why?
Anilides
6
2024
67
1.470
 Why?
Gonanes
7
2016
27
1.440
 Why?
Biomarkers, Tumor
8
2020
1032
1.430
 Why?
Proto-Oncogene Proteins
6
2021
607
1.410
 Why?
Adenocarcinoma
7
2024
787
1.390
 Why?
Thyroid Carcinoma, Anaplastic
3
2020
34
1.360
 Why?
Cetuximab
7
2018
90
1.350
 Why?
Phosphatidylinositol 3-Kinases
8
2017
328
0.900
 Why?
Carcinoma
3
2019
198
0.790
 Why?
Neoplasm Staging
15
2019
1162
0.770
 Why?
Mutation
12
2021
3338
0.760
 Why?
Phytotherapy
2
2012
67
0.750
 Why?
Drugs, Investigational
2
2011
30
0.740
 Why?
Pyrazoles
5
2023
361
0.720
 Why?
Antineoplastic Agents, Immunological
2
2018
152
0.680
 Why?
Disease-Free Survival
10
2017
618
0.680
 Why?
Humans
85
2024
114045
0.680
 Why?
Neoplasms, Second Primary
1
2021
92
0.680
 Why?
Papillomaviridae
4
2019
101
0.670
 Why?
Carcinoma, Renal Cell
3
2017
168
0.660
 Why?
Taxoids
3
2015
93
0.650
 Why?
Hedgehog Proteins
3
2015
172
0.650
 Why?
Colorectal Neoplasms
2
2016
592
0.630
 Why?
Pyrimidines
5
2023
374
0.620
 Why?
Middle Aged
40
2021
26605
0.610
 Why?
Tumor Suppressor Proteins
2
2018
283
0.610
 Why?
Marijuana Smoking
2
2012
224
0.610
 Why?
Kidney Neoplasms
3
2017
324
0.580
 Why?
Aged
36
2024
18969
0.580
 Why?
Carcinoma, Mucoepidermoid
1
2017
15
0.560
 Why?
Ubiquitin Thiolesterase
1
2017
35
0.550
 Why?
Cisplatin
5
2018
262
0.540
 Why?
Carcinoma, Transitional Cell
4
2017
53
0.540
 Why?
Gene Rearrangement
2
2018
135
0.540
 Why?
Carcinoma, Ductal
1
2016
11
0.540
 Why?
Adenoma, Pleomorphic
1
2016
8
0.530
 Why?
Sulfones
2
2014
97
0.530
 Why?
Glycine
2
2014
152
0.530
 Why?
Maximum Tolerated Dose
5
2017
183
0.490
 Why?
Drug Resistance, Neoplasm
7
2021
636
0.480
 Why?
Melanoma
1
2021
620
0.470
 Why?
Enzyme Inhibitors
3
2014
743
0.460
 Why?
Signal Transduction
8
2018
4501
0.450
 Why?
Drug Interactions
6
2017
337
0.450
 Why?
Quinolines
4
2024
129
0.450
 Why?
Male
41
2022
55396
0.440
 Why?
Pyrroles
1
2014
181
0.440
 Why?
Gene Fusion
3
2023
18
0.430
 Why?
Female
42
2022
59324
0.430
 Why?
Genetic Variation
1
2018
868
0.420
 Why?
Receptor Protein-Tyrosine Kinases
2
2012
224
0.420
 Why?
Treatment Outcome
15
2024
9049
0.420
 Why?
Lymph Nodes
4
2017
415
0.410
 Why?
Indazoles
3
2019
57
0.410
 Why?
Aged, 80 and over
14
2020
6306
0.390
 Why?
Class I Phosphatidylinositol 3-Kinases
4
2017
76
0.390
 Why?
Quinazolines
1
2013
240
0.390
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2012
94
0.390
 Why?
Neoplasm Metastasis
6
2021
521
0.370
 Why?
Proto-Oncogene Proteins c-ret
4
2023
27
0.340
 Why?
Cannabinoids
1
2011
115
0.340
 Why?
Prognosis
9
2021
3315
0.340
 Why?
Adult
22
2022
30375
0.320
 Why?
Papillomavirus Infections
3
2022
261
0.310
 Why?
ErbB Receptors
4
2017
554
0.300
 Why?
Pharmacogenomic Variants
2
2018
33
0.290
 Why?
Nitriles
2
2022
149
0.290
 Why?
Urologic Neoplasms
2
2017
24
0.280
 Why?
Acute Kidney Injury
3
2018
637
0.280
 Why?
Carcinoma, Ductal, Breast
1
2007
76
0.270
 Why?
Mitoxantrone
1
2006
12
0.270
 Why?
Gene Expression Profiling
5
2018
1518
0.270
 Why?
Enterobacter
1
2006
7
0.270
 Why?
Tooth Diseases
1
2006
13
0.260
 Why?
Esophageal and Gastric Varices
1
2006
30
0.260
 Why?
Benzamides
2
2019
168
0.260
 Why?
Enterobacteriaceae Infections
1
2006
33
0.260
 Why?
Animals
15
2019
31565
0.260
 Why?
Oropharyngeal Neoplasms
2
2016
39
0.250
 Why?
Clinical Trials as Topic
3
2018
926
0.250
 Why?
Salivary Glands
2
2023
31
0.250
 Why?
Registries
2
2016
1764
0.250
 Why?
Immunotherapy
2
2023
473
0.250
 Why?
Chemoradiotherapy
4
2020
187
0.250
 Why?
Cannabis
1
2011
383
0.240
 Why?
Antibodies, Monoclonal, Humanized
3
2014
660
0.240
 Why?
Receptors, Estrogen
1
2007
371
0.240
 Why?
Xenograft Model Antitumor Assays
6
2019
695
0.240
 Why?
Urinary Bladder Neoplasms
2
2017
196
0.230
 Why?
Gene Expression Regulation, Neoplastic
3
2019
1145
0.230
 Why?
Liver Cirrhosis
1
2006
227
0.230
 Why?
Bacteremia
1
2006
160
0.230
 Why?
Combined Modality Therapy
4
2018
1117
0.220
 Why?
Carcinoma, Adenoid Cystic
1
2023
16
0.220
 Why?
Administration, Oral
3
2014
725
0.220
 Why?
Breast Neoplasms
2
2019
1846
0.210
 Why?
Iodine Radioisotopes
4
2024
126
0.210
 Why?
Referral and Consultation
1
2007
632
0.210
 Why?
Phenylurea Compounds
3
2024
81
0.200
 Why?
Survival Rate
5
2021
1638
0.200
 Why?
Phenylthiohydantoin
1
2022
40
0.200
 Why?
Chemotherapy, Adjuvant
3
2017
332
0.190
 Why?
Drug Evaluation, Preclinical
2
2013
159
0.190
 Why?
Radiation Pneumonitis
1
2021
24
0.190
 Why?
Survival Analysis
4
2020
1206
0.190
 Why?
TOR Serine-Threonine Kinases
2
2016
359
0.180
 Why?
Carcinoma, Neuroendocrine
1
2021
29
0.180
 Why?
Adrenal Cortex Neoplasms
1
2021
48
0.180
 Why?
Adrenocortical Carcinoma
1
2021
47
0.180
 Why?
United States
8
2021
12137
0.180
 Why?
Disease Susceptibility
2
2020
316
0.180
 Why?
SEER Program
1
2021
195
0.170
 Why?
Gene Expression
2
2015
1417
0.170
 Why?
Cystectomy
2
2017
32
0.170
 Why?
Leukemia, Myeloid, Acute
1
2006
533
0.170
 Why?
Kaplan-Meier Estimate
3
2017
813
0.170
 Why?
Receptors, Nerve Growth Factor
1
2019
15
0.170
 Why?
Radiosurgery
1
2022
299
0.170
 Why?
Lymph Node Excision
2
2017
140
0.160
 Why?
DNA Mutational Analysis
2
2018
373
0.160
 Why?
Positron Emission Tomography Computed Tomography
1
2020
67
0.160
 Why?
Prostatic Neoplasms
1
2006
913
0.160
 Why?
Tracheal Neoplasms
1
2019
9
0.160
 Why?
Genomics
3
2021
631
0.160
 Why?
Palliative Care
2
2018
641
0.160
 Why?
Smad4 Protein
1
2019
34
0.160
 Why?
Genetic Heterogeneity
1
2019
47
0.160
 Why?
Benzazepines
1
2018
37
0.150
 Why?
Disease Management
2
2020
556
0.150
 Why?
Alphapapillomavirus
2
2016
36
0.150
 Why?
Chromosome Aberrations
1
2019
134
0.150
 Why?
Risk
1
2021
810
0.150
 Why?
Receptor, ErbB-2
2
2019
300
0.150
 Why?
DNA Mismatch Repair
1
2018
37
0.150
 Why?
Paraffin Embedding
1
2017
21
0.150
 Why?
Tissue Fixation
1
2017
27
0.150
 Why?
Formaldehyde
1
2017
46
0.150
 Why?
Oncogenes
1
2018
104
0.140
 Why?
Smokers
1
2018
129
0.140
 Why?
Erlotinib Hydrochloride
1
2017
64
0.140
 Why?
Young Adult
5
2021
10444
0.140
 Why?
Nasopharyngeal Neoplasms
1
2017
13
0.140
 Why?
Radiotherapy, Intensity-Modulated
1
2018
124
0.140
 Why?
Neoplasm Grading
1
2018
241
0.140
 Why?
Health Services Needs and Demand
1
2019
240
0.140
 Why?
Gene Deletion
1
2019
356
0.140
 Why?
DNA, Neoplasm
1
2017
155
0.140
 Why?
Induction Chemotherapy
1
2017
56
0.140
 Why?
Retrospective Studies
8
2021
12521
0.140
 Why?
Patient Navigation
1
2018
63
0.140
 Why?
Gene Frequency
1
2018
476
0.140
 Why?
Hospice and Palliative Care Nursing
1
2018
69
0.140
 Why?
Disease Progression
4
2018
2371
0.140
 Why?
Chemoradiotherapy, Adjuvant
1
2016
40
0.140
 Why?
Salivary Ducts
1
2016
3
0.130
 Why?
Computational Biology
2
2018
528
0.130
 Why?
Laryngeal Neoplasms
1
2016
27
0.130
 Why?
Nomograms
1
2016
41
0.130
 Why?
Muscle, Smooth
1
2017
142
0.130
 Why?
Carboplatin
1
2016
135
0.130
 Why?
Population Surveillance
1
2019
385
0.130
 Why?
Dose-Response Relationship, Drug
3
2017
1836
0.130
 Why?
Incidence
2
2019
2314
0.130
 Why?
Database Management Systems
1
2016
47
0.130
 Why?
Bone Neoplasms
1
2017
191
0.120
 Why?
Genetic Testing
1
2018
381
0.120
 Why?
Angiopoietin-1
1
2015
10
0.120
 Why?
Angiopoietin-2
1
2015
11
0.120
 Why?
Radiotherapy
1
2016
175
0.120
 Why?
Zinc Finger Protein GLI1
1
2014
21
0.120
 Why?
Retreatment
1
2014
67
0.120
 Why?
Hospice Care
1
2018
184
0.120
 Why?
Piperazines
2
2018
310
0.120
 Why?
Neoplasms, Unknown Primary
1
2014
12
0.120
 Why?
Neoplastic Stem Cells
1
2018
327
0.120
 Why?
Response Evaluation Criteria in Solid Tumors
1
2014
14
0.120
 Why?
Prospective Studies
6
2024
6195
0.110
 Why?
Pilot Projects
2
2015
1360
0.110
 Why?
Patient Satisfaction
1
2018
571
0.110
 Why?
Proto-Oncogene Proteins c-akt
1
2016
397
0.110
 Why?
Paclitaxel
1
2015
190
0.110
 Why?
High-Throughput Nucleotide Sequencing
1
2017
437
0.110
 Why?
Sulfonamides
1
2017
444
0.110
 Why?
Proportional Hazards Models
4
2017
1078
0.110
 Why?
Promoter Regions, Genetic
1
2018
1131
0.110
 Why?
ras Proteins
1
2014
138
0.110
 Why?
Veratrum Alkaloids
1
2013
17
0.110
 Why?
PTEN Phosphohydrolase
1
2014
140
0.110
 Why?
Cell Cycle Proteins
2
2014
549
0.110
 Why?
Proto-Oncogene Proteins p21(ras)
1
2014
228
0.110
 Why?
Biomarkers
3
2018
3397
0.110
 Why?
Risk Assessment
2
2019
2958
0.100
 Why?
Imatinib Mesylate
1
2012
63
0.100
 Why?
Adolescent
5
2022
17800
0.100
 Why?
Dasatinib
1
2012
45
0.100
 Why?
Recombinant Fusion Proteins
1
2015
613
0.100
 Why?
Aniline Compounds
1
2012
70
0.100
 Why?
Tumor Microenvironment
1
2015
428
0.100
 Why?
Hematopoietic Stem Cells
1
2015
338
0.100
 Why?
Thiazoles
1
2012
110
0.100
 Why?
Smoking
1
2019
1382
0.100
 Why?
Propensity Score
3
2017
225
0.100
 Why?
Proto-Oncogene Proteins c-met
1
2012
67
0.100
 Why?
Biological Availability
1
2011
119
0.090
 Why?
Imidazoles
1
2012
203
0.090
 Why?
Carcinoma, Basal Cell
1
2012
66
0.090
 Why?
Evidence-Based Medicine
2
2012
662
0.090
 Why?
Phosphatidylinositol 3-Kinase
1
2011
26
0.090
 Why?
Vascular Endothelial Growth Factor A
2
2024
496
0.090
 Why?
Algorithms
1
2018
1469
0.090
 Why?
Phenotype
1
2018
2784
0.090
 Why?
Brain Neoplasms
1
2018
966
0.090
 Why?
Kidney
1
2017
1182
0.090
 Why?
Genetic Predisposition to Disease
1
2018
2090
0.090
 Why?
Adaptation, Psychological
1
2014
545
0.090
 Why?
Mice
6
2019
14843
0.080
 Why?
Models, Biological
2
2020
1611
0.080
 Why?
Multivariate Analysis
3
2017
1422
0.080
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2024
103
0.080
 Why?
Cohort Studies
4
2022
4883
0.080
 Why?
Neoadjuvant Therapy
2
2022
305
0.070
 Why?
Caregivers
1
2014
713
0.070
 Why?
Axilla
1
2007
39
0.070
 Why?
RNA, Messenger
1
2014
2550
0.070
 Why?
Clinical Trials, Phase I as Topic
2
2019
45
0.070
 Why?
Mastectomy
1
2007
99
0.070
 Why?
Transcription Factors
1
2014
1526
0.070
 Why?
Sentinel Lymph Node Biopsy
1
2007
99
0.070
 Why?
Stress, Psychological
1
2014
944
0.070
 Why?
Ligation
1
2006
75
0.070
 Why?
Creatinine
2
2018
424
0.060
 Why?
Pain
1
2011
701
0.060
 Why?
Risk Factors
1
2019
8614
0.060
 Why?
Double-Blind Method
2
2021
1656
0.060
 Why?
Lymphatic Metastasis
2
2017
275
0.060
 Why?
Neoplasm Invasiveness
2
2017
438
0.060
 Why?
Fatal Outcome
1
2006
281
0.060
 Why?
Receptors, Progesterone
1
2007
319
0.060
 Why?
Gastrointestinal Hemorrhage
1
2006
101
0.060
 Why?
Skin Neoplasms
1
2012
754
0.060
 Why?
Glomerular Filtration Rate
2
2018
605
0.060
 Why?
Cell Line, Tumor
3
2018
2700
0.060
 Why?
Neoplasm Proteins
1
2007
385
0.060
 Why?
Demography
2
2015
258
0.060
 Why?
Recurrence
2
2018
925
0.050
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2023
86
0.050
 Why?
Databases, Factual
2
2019
1125
0.050
 Why?
Quality of Life
1
2013
2343
0.050
 Why?
Androgen Antagonists
1
2022
69
0.050
 Why?
Four-Dimensional Computed Tomography
1
2021
25
0.050
 Why?
Immunohistochemistry
2
2018
1624
0.050
 Why?
Pulmonary Ventilation
1
2021
72
0.050
 Why?
Receptors, Androgen
1
2022
131
0.050
 Why?
Radiotherapy Planning, Computer-Assisted
1
2021
117
0.050
 Why?
Receptor, trkC
1
2019
10
0.040
 Why?
Receptor, trkA
1
2019
16
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2019
59
0.040
 Why?
Receptor, trkB
1
2019
28
0.040
 Why?
Trastuzumab
1
2019
89
0.040
 Why?
Extracellular Signal-Regulated MAP Kinases
1
2020
157
0.040
 Why?
Radiotherapy, Image-Guided
1
2018
30
0.040
 Why?
Phthalazines
1
2018
38
0.040
 Why?
Proto-Oncogene Proteins B-raf
1
2020
191
0.040
 Why?
In Situ Hybridization, Fluorescence
1
2019
308
0.040
 Why?
Organic Cation Transporter 2
1
2017
8
0.040
 Why?
Glutathione S-Transferase pi
1
2017
8
0.040
 Why?
Platinum
1
2017
38
0.040
 Why?
Multidrug Resistance-Associated Proteins
1
2017
34
0.040
 Why?
Membrane Glycoproteins
1
2019
429
0.040
 Why?
Retroperitoneal Space
1
2017
14
0.040
 Why?
Organic Cation Transport Proteins
1
2017
26
0.040
 Why?
Disease Models, Animal
2
2018
3498
0.040
 Why?
Urinary Diversion
1
2017
11
0.040
 Why?
Margins of Excision
1
2017
29
0.040
 Why?
National Cancer Institute (U.S.)
1
2017
40
0.030
 Why?
Social Work
1
2018
74
0.030
 Why?
Tumor Cells, Cultured
1
2019
845
0.030
 Why?
Immunophenotyping
1
2018
274
0.030
 Why?
Anti-Bacterial Agents
1
2006
1471
0.030
 Why?
Laryngectomy
1
2016
13
0.030
 Why?
Oncologists
1
2017
30
0.030
 Why?
Hospitals, Veterans
1
2018
244
0.030
 Why?
Carcinogenesis
1
2018
175
0.030
 Why?
Kidney Function Tests
1
2017
140
0.030
 Why?
Pelvis
1
2017
89
0.030
 Why?
Cation Transport Proteins
1
2017
123
0.030
 Why?
Viral Core Proteins
1
2016
20
0.030
 Why?
Heart
1
2020
613
0.030
 Why?
Radiotherapy, Adjuvant
1
2016
182
0.030
 Why?
Regression Analysis
1
2018
945
0.030
 Why?
Internationality
1
2016
143
0.030
 Why?
Random Allocation
1
2016
328
0.030
 Why?
Robotic Surgical Procedures
1
2017
86
0.030
 Why?
Antibodies, Neoplasm
1
2015
30
0.030
 Why?
Myocardium
1
2020
911
0.030
 Why?
Biopsy, Large-Core Needle
1
2014
11
0.030
 Why?
Analysis of Variance
1
2017
1218
0.030
 Why?
Bone Marrow
1
2015
243
0.030
 Why?
Receptor, Notch2
1
2013
14
0.030
 Why?
Receptor Cross-Talk
1
2013
20
0.030
 Why?
Transcriptome
1
2018
723
0.030
 Why?
Pandemics
1
2021
1310
0.030
 Why?
Receptor, Notch1
1
2013
59
0.030
 Why?
Needs Assessment
1
2014
315
0.030
 Why?
Gene Silencing
1
2013
171
0.030
 Why?
Psychiatric Status Rating Scales
1
2014
481
0.030
 Why?
Metabolic Clearance Rate
1
2012
102
0.020
 Why?
Logistic Models
1
2017
1829
0.020
 Why?
Nausea
1
2012
99
0.020
 Why?
Vomiting
1
2012
122
0.020
 Why?
Area Under Curve
1
2012
273
0.020
 Why?
Mice, Nude
1
2013
628
0.020
 Why?
Diarrhea
1
2012
170
0.020
 Why?
Fatigue
1
2012
294
0.020
 Why?
Blotting, Western
1
2013
1143
0.020
 Why?
Cell Proliferation
1
2017
2173
0.020
 Why?
Drug Administration Schedule
1
2012
714
0.020
 Why?
Time Factors
1
2019
6077
0.020
 Why?
Lung
1
2021
3521
0.020
 Why?
Age Factors
1
2016
2885
0.020
 Why?
Colorado
1
2018
4090
0.020
 Why?
Follow-Up Studies
1
2016
4392
0.020
 Why?
Cytokines
1
2015
1824
0.020
 Why?
Surveys and Questionnaires
1
2018
4595
0.020
 Why?
Cross-Sectional Studies
1
2014
4402
0.010
 Why?
Bowles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (339) concept(s)
_
Co-Authors Expand Description
See all (64) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)